Takeda Pharmaceutical Co Ltd Oncology Strategic Update Call Transcript
Thanks for joining oncology strategic update. We're looking forward to taking a deeper dive into our oncology pipeline. We have about a 40-minute presentation for you guys today, and the remainder of the time will be used for Q&A. We are hoping that the Q&A is very interactive. So if you have a question, please ask it through the Zoom platform by raising your hand with the raise hand function at the bottom of the screen.
Today, joining us is Teresa Bitetti, President of Global Oncology Business Unit; and Chris Arendt, Head of Oncology Therapeutic area. We also have Andy Plump, President of Research and I and some other members from the oncology team that will be joining for the Q&A session.
Before we start, I'd like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, actual results may vary materially from those disclosed today. The factors that could cause our actual results to differ materially are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
